Ocular Therapeutix will participate in December conferences highlighting advancements in retinal disease therapies and ongoing clinical trials.
Quiver AI Summary
Ocular Therapeutix, Inc., a biopharmaceutical company focused on developing innovative therapies for retinal diseases, announced its participation in several upcoming investor and scientific conferences in December 2024. Notably, Executive Chairman Dr. Pravin U. Dugel will present at the Piper Sandler 36th Annual Healthcare Conference on December 3rd. The company will also showcase results from its HELIOS Phase I trial of OTX-TKI for non-proliferative diabetic retinopathy at the FLORetina ICOOR 2024 conference in Florence, Italy, with presentations scheduled for December 5th and 6th. Ocular's product pipeline includes AXPAXLI™, currently in Phase 3 trials for wet age-related macular degeneration, and DEXTENZA®, an FDA-approved treatment for ocular inflammation, among others.
Potential Positives
- Ocular Therapeutix is participating in multiple high-profile investor and scientific conferences in December, showcasing its commitment to transparency and engagement with the investment community.
- Presentation of 48-week results from the HELIOS Phase I trial for OTX-TKI at the FLORetina ICOOR 2024 highlights the company’s proactive approach in sharing clinical progress, which may boost investor confidence.
- The presence of key executives, including the Executive Chairman and other MDs, at these conferences underscores the company’s leadership and strategic vision in the retinal disease market.
- The upcoming presentations focus on innovative therapies for serious eye conditions, positioning Ocular Therapeutix as a leader in the development of advanced biopharmaceutical solutions for retinal diseases.
Potential Negatives
- The press release does not provide any new product approvals or significant clinical advancements, which could indicate stagnation in the company's progress in its therapeutic development.
- The focus on upcoming conferences might suggest that the company is struggling to generate investor interest or excitement for its current products and pipeline.
- The mention of ongoing clinical trials without any new positive results may raise concerns regarding the efficacy and future potential of its key product candidate AXPAXLI.
FAQ
What events will Ocular Therapeutix participate in December 2024?
Ocular Therapeutix will participate in several investor and scientific conferences, including the Piper Sandler Healthcare Conference and FLORetina ICOOR 2024.
Who is presenting at the Piper Sandler Conference?
Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix will present at the Piper Sandler Conference.
What is AXPAXLI and its significance?
AXPAXLI is Ocular’s product candidate for retinal disease, currently in Phase 3 clinical trials for wet age-related macular degeneration.
What technology does AXPAXLI utilize?
AXPAXLI utilizes Ocular's proprietary ELUTYX technology, a bioresorbable hydrogel-based formulation.
How can I access the live fireside chat?
The live fireside chat can be accessed via the Ocular Therapeutix website in the Events and Presentations section of the Investor Relations page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- SANJAY NAYAK (Chief Strategy Officer) sold 1,832 shares.
- PRAVIN DUGEL (See Remarks) sold 20,880 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 76 institutional investors add shares of $OCUL stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. added 2,825,756 shares (+inf%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 1,728,723 shares (-100.0%) from their portfolio in Q2 2024
- LOGOS GLOBAL MANAGEMENT LP removed 1,650,000 shares (-32.0%) from their portfolio in Q3 2024
- ACUTA CAPITAL PARTNERS, LLC removed 1,581,059 shares (-57.1%) from their portfolio in Q3 2024
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,056,092 shares (+inf%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 1,000,000 shares (+inf%) to their portfolio in Q3 2024
- INVESCO LTD. added 709,573 shares (+1545.9%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.
Piper Sandler 36
th
Annual Healthcare Conference
Fireside Chat Date: Tuesday, December 3rd, 2024
Fireside Chat Time: 1:30 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York City, NY
The live fireside chat can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
FLORetina ICOOR 2024
Florence, Italy
-
48-week Results from the HELIOS Phase I Trial Evaluating Intravitreal OTX-TKI for Non-proliferative Diabetic Retinopathy
Session: Highlighted New Drugs DME
Presentation Date/Time: Thursday, December 5, 2024, 1:33 – 1:36PM CET
Presenter: Dilsher S. Dhoot, MD
-
OTX-TKI – The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
Presentation Date/Time Friday, December 6, 2024, 11:29 – 11:33AM CET
Presenter: Diana V. Do, MD
-
HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
Session: Retina Futura 2: Diabetic Retinal Diseases and Retinal Detachment
Presentation Date/Time: Friday, December 6, 2024, 2:12 – 2:16PM CET
Presenter: Dilsher S. Dhoot, MD
-
TKIs in the Future of Retinal Disease Management
Session: Afternoon Symposium
Session Date/Time: Saturday, December 7, 2024, 3:30 – 4:30 PM CET
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
